Castle Biosciences Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 35c, Revenues Beat
November 11, 2019 4:06 PM ESTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of $0.05, $0.35 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $14.78 million versus the consensus estimate of $9.45 million.
We are pleased with our strong third quarter performance, driven by solid growth in our DecisionDx®-Melanoma test report volume, which is a result of our investment in evidence development and scaling our commercial team... More
